TrialBMC medicine2019

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.

Joaquín Gavilá et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.